Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D
Substance use disorders provide challenges for development of effective medications. Use of abused substances is likely initiated, sustained and “quit” by complex brain and pharmacological mechanisms that have both genetic and environmental determinants. Medical utilities of prescribed stimulants an...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1031283/full |
| _version_ | 1797845539173171200 |
|---|---|
| author | George R. Uhl George R. Uhl |
| author_facet | George R. Uhl George R. Uhl |
| author_sort | George R. Uhl |
| collection | DOAJ |
| description | Substance use disorders provide challenges for development of effective medications. Use of abused substances is likely initiated, sustained and “quit” by complex brain and pharmacological mechanisms that have both genetic and environmental determinants. Medical utilities of prescribed stimulants and opioids provide complex challenges for prevention: how can we minimize their contribution to substance use disorders while retaining medical benefits for pain, restless leg syndrome, attention deficit hyperactivity disorder, narcolepsy and other indications. Data required to support assessments of reduced abuse liability and resulting regulatory scheduling differs from information required to support licensing of novel prophylactic or therapeutic anti-addiction medications, adding further complexity and challenges. I describe some of these challenges in the context of our current efforts to develop pentilludin as a novel anti-addiction therapeutic for a target that is strongly supported by human and mouse genetic and pharmacologic studies, the receptor type protein tyrosine phosphatase D (PTPRD). |
| first_indexed | 2024-04-09T17:40:39Z |
| format | Article |
| id | doaj.art-66345e6601c14147a229bea2534a352f |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-09T17:40:39Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-66345e6601c14147a229bea2534a352f2023-04-17T05:30:02ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402023-04-011410.3389/fpsyt.2023.10312831031283Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase DGeorge R. Uhl0George R. Uhl1Departments of Neurology and Pharmacology, University of Maryland School of Medicine, Neurology Service, VA Maryland Healthcare System, Baltimore, MD, United StatesDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United StatesSubstance use disorders provide challenges for development of effective medications. Use of abused substances is likely initiated, sustained and “quit” by complex brain and pharmacological mechanisms that have both genetic and environmental determinants. Medical utilities of prescribed stimulants and opioids provide complex challenges for prevention: how can we minimize their contribution to substance use disorders while retaining medical benefits for pain, restless leg syndrome, attention deficit hyperactivity disorder, narcolepsy and other indications. Data required to support assessments of reduced abuse liability and resulting regulatory scheduling differs from information required to support licensing of novel prophylactic or therapeutic anti-addiction medications, adding further complexity and challenges. I describe some of these challenges in the context of our current efforts to develop pentilludin as a novel anti-addiction therapeutic for a target that is strongly supported by human and mouse genetic and pharmacologic studies, the receptor type protein tyrosine phosphatase D (PTPRD).https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1031283/fullreceptor type protein tyrosine phosphataselapse dosesrelapseantiaddiction drug developmentinhibitors of protein tyrosine phosphatase |
| spellingShingle | George R. Uhl George R. Uhl Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D Frontiers in Psychiatry receptor type protein tyrosine phosphatase lapse doses relapse antiaddiction drug development inhibitors of protein tyrosine phosphatase |
| title | Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D |
| title_full | Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D |
| title_fullStr | Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D |
| title_full_unstemmed | Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D |
| title_short | Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D |
| title_sort | selecting the appropriate hurdles and endpoints for pentilludin a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase d |
| topic | receptor type protein tyrosine phosphatase lapse doses relapse antiaddiction drug development inhibitors of protein tyrosine phosphatase |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1031283/full |
| work_keys_str_mv | AT georgeruhl selectingtheappropriatehurdlesandendpointsforpentilludinanovelantiaddictionpharmacotherapeutictargetingthereceptortypeproteintyrosinephosphatased AT georgeruhl selectingtheappropriatehurdlesandendpointsforpentilludinanovelantiaddictionpharmacotherapeutictargetingthereceptortypeproteintyrosinephosphatased |